Search clinical trials for: RT and Anti-PD-1

Total 95498 results

Agenus Inc.

Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Melanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver Metastases

United States
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Symphogen A/S

Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma | Solid Tumor | Metastatic Cancer

Canada, United States
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Fudan University

Withdrawn

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Intrahepatic Cholangiocarcinoma

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction (TRACE)

Esophageal Cancer

China
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Hospices Civils de Lyon

Completed

Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

Hodgkin Lymphoma

France
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Guangxi Medical University

Unknown

RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)

Hepatocellular Carcinoma
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Hypofractionated Proton Therapy With Immunotherapy (I-HypoPT)

Immunotherapy | Proton Therapy
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Jounce Therapeutics, Inc.

Completed

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Beijing Friendship Hospital

Recruiting

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma
Novita Pharmaceuticals, Inc.

Recruiting

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

Rectal Squamous Cell Carcinoma

China
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Neoadjuvant Chemoimmunotherapy

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China

Search clinical trials for: RT and Anti-PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations